• +1-646-491-9876
    • +91-20-67278686

    Search

    Cytomegalovirus (HHV-5) Infections Pipeline Review H1 2017

    Cytomegalovirus (HHV-5) Infections Pipeline Review H1 2017

    • Report Code ID: RW0001799310
    • Category Pharmaceuticals
    • No. of Pages 164
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.

    Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 7, 7, 2, 19, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 10, 4 and 4 molecules, respectively.

    Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cytomegalovirus (HHV-5) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus (HHV-5) Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 5
    Cytomegalovirus (HHV-5) Infections - Overview 6
    Cytomegalovirus (HHV-5) Infections - Therapeutics Development 7
    Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 19
    Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 27
    Cytomegalovirus (HHV-5) Infections - Drug Profiles 41
    Cytomegalovirus (HHV-5) Infections - Dormant Projects 142
    Cytomegalovirus (HHV-5) Infections - Discontinued Products 145
    Cytomegalovirus (HHV-5) Infections - Product Development Milestones 146
    Appendix 156

    List of Tables

    Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics BV, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by AvidBiotics Corp, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax BV, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corp LLC, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea SA, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Mymetics Corp, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Qurient Co Ltd, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau SpA, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Theravectys SA, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Inc, H1 2017
    Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2017
    Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AIMM Therapeutics BV
    Astellas Pharma Inc
    Atara Biotherapeutics Inc
    AvidBiotics Corp
    Biotest AG
    Chimerix Inc
    China Biologic Products Inc
    CyTuVax BV
    Fate Therapeutics Inc
    GlaxoSmithKline Plc
    Hookipa Biotech AG
    Kadmon Corp LLC
    Laboratoires Thea SA
    Merck & Co Inc
    Microbiotix Inc
    Mymetics Corp
    Novartis AG
    Pfizer Inc
    Phoenix Biotechnology Inc
    Qurient Co Ltd
    Sigma-Tau SpA
    Themis Bioscience GmbH
    Theravectys SA
    Trellis Bioscience Inc
    Vakzine Projekt Management GmbH
    VBI Vaccines Inc
    Vical Inc

    Request for Sample

    Report Url http://www.reportsweb.com//cytomegalovirus-hhv-5-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cytomegalovirus-hhv-5-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cytomegalovirus-hhv-5-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments